Ensign Peak Advisors Inc Has $20.64 Million Stake in Penumbra, Inc. (NYSE:PEN)

Ensign Peak Advisors Inc cut its stake in Penumbra, Inc. (NYSE:PEN - Free Report) by 31.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 86,912 shares of the company's stock after selling 39,966 shares during the period. Ensign Peak Advisors Inc owned 0.23% of Penumbra worth $20,640,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Barclays PLC increased its position in shares of Penumbra by 16.5% in the 3rd quarter. Barclays PLC now owns 18,025 shares of the company's stock valued at $3,502,000 after buying an additional 2,559 shares in the last quarter. Pallas Capital Advisors LLC increased its holdings in shares of Penumbra by 3.8% in the fourth quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company's stock worth $263,000 after acquiring an additional 41 shares in the last quarter. Park Avenue Securities LLC raised its position in shares of Penumbra by 18.6% during the fourth quarter. Park Avenue Securities LLC now owns 1,665 shares of the company's stock worth $395,000 after purchasing an additional 261 shares during the period. Diversify Wealth Management LLC raised its position in shares of Penumbra by 36.3% during the fourth quarter. Diversify Wealth Management LLC now owns 1,645 shares of the company's stock worth $412,000 after purchasing an additional 438 shares during the period. Finally, UMB Bank n.a. lifted its holdings in shares of Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after purchasing an additional 70 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PEN. BTIG Research reiterated a "buy" rating on shares of Penumbra in a report on Thursday, April 24th. Wells Fargo & Company increased their target price on Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Truist Financial boosted their price target on Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a report on Thursday, April 24th. Bank of America started coverage on Penumbra in a research report on Friday, March 14th. They set a "buy" rating and a $320.00 price objective for the company. Finally, Robert W. Baird lifted their target price on Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $302.40.

Penumbra Stock Performance

NYSE:PEN traded down $13.02 during mid-day trading on Thursday, hitting $275.95. The stock had a trading volume of 1,429,694 shares, compared to its average volume of 437,333. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The stock has a market cap of $10.69 billion, a price-to-earnings ratio of 811.62, a PEG ratio of 2.83 and a beta of 0.53. The company's 50 day simple moving average is $278.62 and its 200 day simple moving average is $262.40.

Penumbra (NYSE:PEN - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.66 by $0.17. The company had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm's revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.41 EPS. On average, equities research analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Insider Buying and Selling at Penumbra

In related news, CFO Maggie Yuen sold 2,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $286.00, for a total value of $572,000.00. Following the transaction, the chief financial officer now directly owns 15,243 shares in the company, valued at approximately $4,359,498. This represents a 11.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Johanna Roberts sold 600 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00. Following the transaction, the executive vice president now directly owns 66,539 shares in the company, valued at $19,125,304.77. This represents a 0.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 159,996 shares of company stock worth $45,228,678 over the last ninety days. Insiders own 4.20% of the company's stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.